Update on targeted therapies for small cell carcinoma of the lung

Targeted Oncology

Volumn 3, Issue 3, 2008, Pages 205-215

  Griffiths, Richard W ^a   Lorigan, Paul ^a   Thatcher, Nicholas ^a   Blackhall, Fiona H ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Small cell lung cancer; Targeted therapy

Indexed keywords

EID: 49749096776     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-008-0086-5     Document Type: Review

References (79)

1. American Cancer Society (2007) Cancer facts and figures 2007. American Cancer Society, Atlanta, GA
2. MLG Janssen-Heijnen J-WW Coebergh 2003 The changing epidemiology of lung cancer in Europe Lung Cancer 41 3 245 258
3. F Veglia P Vineis K Overvad 2007 Occupational exposures, environmental tobacco smoke, and lung cancer Epidemiology 18 6 769 775
4. AT Turrisi K Kim R Blum 1999 Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide N Engl J Med 340 4 265 271
5. R Govindan N Page D Morgensztern 2006 Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database J Clin Oncol 24 28 4539 4544
6. N Murray AT Turrisi 3rd 2006 A review of first-line treatment for small-cell lung cancer J Thorac Oncol 1 3 270 278
7. BJ Druker NB Lydon 2000 Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia J Clin Invest 105 1 3 7
8. GD Demetri M von Mehren CD Blanke 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 7 472 480
9. FH Blackhall M Pintilie M Michael 2003 Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer Clin Cancer Res 9 6 2241 2247
10. LM Krug JP Crapanzano CG Azzoli 2005 Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial Cancer 103 10 2128 2131
11. A Potti N Moazzam K Ramar 2003 CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma Ann Oncol 14 6 894 897
12. BE Johnson T Fischer B Fischer 2003 Phase II study of imatinib in patients with small cell lung cancer Clin Cancer Res 9 16 Pt 1 5880 5887
13. GK Dy AA Miller SJ Mandrekar 2005 A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study Ann Oncol 16 11 1811 1816
14. B Schneider S Gadgeel N Ramnath 2006 Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-kit positive extensive-stage small cell lung cancer (ES SCLC) J Clin Oncol 24 18S 17089
15. N Takigawa M Takeyama T Kozuki 2007 Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells Oncol Rep 17 5 983 987
16. FM Johnson LM Krug HT Tran 2006 Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma Cancer 106 2 366 374
17. DR Spigel JD Hainsworth L Simons 2007 Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network J Thorac Oncol 2 9 854 861
18. GW Krystal S Honsawek J Litz 2000 The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth Clin Cancer Res 6 8 3319 3326
19. M Brave V Goodman E Kaminskas 2008 Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate Clin Cancer Res 14 2 352 359
20. S Roelle R Grosse T Buech 2008 Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells Oncogene 27 12 1737 1748
21. GW Krystal CS DeBerry D Linnekin 1998 Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1 Cancer Res 58 20 4660 4666
22. LF Hennequin J Allen J Breed 2006 N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2- (4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy) quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor J Med Chem 49 22 6465 6488
23. NM Appels JH Beijnen JH Schellens 2005 Development of farnesyl transferase inhibitors: a review Oncologist 10 8 565 578
24. JV Heymach DH Johnson FR Khuri 2004 Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer Ann Oncol 15 8 1187 1193
25. AM Moore LH Einhorn D Estes 2006 Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial Lung Cancer 52 1 93 97
26. LE Heasley 2001 Autocrine and paracrine signaling through neuropeptide receptors in human cancer Oncogene 20 13 1563 1569
27. PJ Woll E Rozengurt 1990 A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro Cancer Res 50 13 3968 3973
28. TW Moody J Chiles M Casibang 2001 SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells Peptides 22 1 109 115
29. MM Mita A Mita EK Rowinsky 2003 The molecular target of rapamycin (mTOR) as a therapeutic target against cancer Cancer Biol Ther 2 4 Suppl 1 S169 S177
30. KJ Pandya S Dahlberg M Hidalgo 2007 A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500) J Thorac Oncol 2 11 1036 1041
31. M Steegmaier M Hoffmann A Baum 2007 BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo Curr Biol 17 4 316 322
32. RG Advani M Hurwitz D Mendelson H Wakelee S Ebbinghaus U Hoch J Silverman N Havrilla D Adelman 2005 Phase I trial of SNS-595 in patients with advanced malignancies J Clin Oncol 23 16S 2099
33. V Sandor S Bakke RW Robey 2002 Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms Clin Cancer Res 8 3 718 728
34. S Doi H Soda M Oka 2004 The histone deacetylase inhibitor FR901228 induces caspase-dependent apoptosis via the mitochondrial pathway in small cell lung cancer cells Mol Cancer Ther 3 11 1397 1402
35. JM Adams S Cory 2007 The Bcl-2 apoptotic switch in cancer development and therapy Oncogene 26 9 1324 1337
36. N Shivapurkar J Reddy PM Chaudhary 2003 Apoptosis and lung cancer: a review J Cell Biochem 88 5 885 898
37. TC Fisher AE Milner CD Gregory 1993 bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways Cancer Res 53 14 3321 3326
38. CM Rudin GA Otterson AM Mauer 2002 A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer Ann Oncol 13 4 539 545
39. CM Rudin M Kozloff PC Hoffman 2004 Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer J Clin Oncol 22 6 1110 1117
40. CM Rudin R Salgia X Wang 2008 Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103 J Clin Oncol 26 6 870 876
41. R Kim M Emi K Matsuura 2007 Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy Cancer Gene Ther 14 1 1 11
42. R Lock H Carol PJ Houghton 2007 Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program Pediatr Blood Cancer 50 1198 1206
43. M Nguyen RC Marcellus A Roulston 2007 Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis Proc Natl Acad Sci USA 104 49 19512 19517
44. H Pitot M Saleh J Holmlund J Maleski A Forero 2007 Extended phase I trial of the oral pan-Bcl-2 inhibitor AT-101 by multiple dosing schedules in patients with advanced cancers Proc Am Soc Clin Oncol 25 18S 3583
45. PN Lara Jr. RJ Bold PC Mack 2005 Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications Clin Lung Cancer 7 Suppl 2 S67 S71
46. PN Lara Jr. K Chansky AM Davies 2006 Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327) J Thorac Oncol 1 9 996 1001
47. P Salven T Ruotsalainen K Mattson 1998 High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small-cell lung cancer Int J Cancer 79 2 144 146
48. E Raefsky DR Spigel FA Greco DA Yardley JE Bradof DV Woytowitz MT Schreeder JH Liggett JD Zubkus D Petrone JD Hainsworth 2005 Irinotecan (I), carboplatin (C), and radiotherapy (RT) followed by bevacizumab (B) in the treatment of limited-stage small cell lung cancer (SCLC): a phase II trial of the Minnie Pearl Cancer Research Network Proc Am Soc Clin Oncol 23 16S 7050
49. Barron H (2007) MedWatch safety alert. Available at: http://www.fda.gov/ medwatch/safety/2007/Avastin_DHCP_TEF_Final_April2007.pdf
50. N Ready AZ Dudek XF Wang 2007 CALGB 30306: A phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC) Proc Am Soc Clin Oncol 25 18S 7563
51. A Sandler S Szwaric A Dowlati 2007 A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously untreated extensive stage small cell lung cancer (SCLC) (E3501): a trial of the Eastern Cooperative Oncology Group Proc Am Soc Clin Oncol 25 18S 7564
52. D Spigel JD Hainsworth DA Yardley HA Burris C Farley J Zubkus C Meng P Murphy R Saez FA Greco 2007 Phase II trial of irinotecan, carboplatin, and bevacizumab in patients with extensive-stage small cell lung cancer Proc Am Soc Clin Oncol 25 18S 18130
53. AM Arnold L Seymour M Smylie 2007 Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20 J Clin Oncol 25 27 4278 4284
54. J Drevs P Siegert M Medinger 2007 Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors J Clin Oncol 25 21 3045 3054
55. SS Ramalingam PC Mack EE Vokes 2008 Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097) Proc Am Soc Clin Oncol 26 8078
56. BJ Gitlitz BS Glisson J Moon 2008 Sorafenib in patients with platinum (plat) treated extensive stage small cell lung cancer (E-SCLC): a SWOG (S0435) phase II trial Proc Am Soc Clin Oncol 26 8039
57. JL Pujol JL Breton R Gervais 2006 A prospective randomized phase III, double-blind, placebo-controlled study of thalidomide in extended-disease (ED) SCLC patients after response to chemotherapy (CT): An intergroup study FNCLCC Cleo04-IFCT 00-01 Proc Am Soc Clin Oncol 24 18S 17089
58. JL Pujol JL Breton R Gervais 2007 Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01 J Clin Oncol 25 25 3945 3951
59. SW Lee PJ Woll LE James M Hatton K Ali SG Spiro SR Ali A Hackshaw 2007 A phase III randomised, double blind, placebo controlled trial of etoposide/carboplatin with or without thalidomide in advanced small cell lung cancer (SCLC) J Thor Oncol 2 Suppl 4 S306
60. JR Jett AW Maksymiuk JQ Su 1994 Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer J Clin Oncol 12 11 2321 2326
61. K Kelly JJ Crowley PA Bunn Jr. 1995 Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study J Clin Oncol 13 12 2924 2930
62. B Lebeau PDL Salmoniere G Ozenne 1999 Alpha interferon as maintenance therapy for small cell lung cancer (SCLC) Proc Am Soc Clin Oncol 18 475a
63. K Mattson A Niiranen S Pyrhonen 1991 Recombinant interferon gamma treatment in non-small cell lung cancer. Antitumour effect and cardiotoxicity Acta Oncol 30 5 607 610
64. G Giaccone C Debruyne E Felip 2005 Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study) J Clin Oncol 23 28 6854 6864
65. SJ Antonia N Mirza I Fricke 2006 Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer Clin Cancer Res 12 3 Pt 1 878 887
66. TJ Lynch Jr. JM Lambert F Coral 1997 Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin J Clin Oncol 15 2 723 734
67. LM Krug DT Milton AA Jungbluth 2007 Targeting Lewis Y (Le(y)) in small cell lung cancer with a humanized monoclonal antibody, hu3S193: a pilot trial testing two dose levels J Thorac Oncol 2 10 947 952
68. RA Peck J Hewett MW Harding 2001 Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin J Clin Oncol 19 12 3130 3141
69. JA Maroun K Belanger L Seymour 2006 Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115 Ann Oncol 17 9 1371 1378
70. FA Shepherd G Giaccone L Seymour 2002 Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer J Clin Oncol 20 22 4434 4439
71. C Erlichman AA Adjei SR Alberts 2001 Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566 Ann Oncol 12 3 389 395
72. A Sandler R Gray MC Perry 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 24 2542 2550
73. R Harrop N Drury W Shingler 2008 Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses Cancer Immunol Immunother 57 7 977 986
74. G Maulik T Kijima PC Ma 2002 Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer Clin Cancer Res 8 2 620 627
75. J Sarvesvaran JJ Going R Milroy 1999 Is small cell lung cancer the perfect target for anti-telomerase treatment? Carcinogenesis 20 8 1649 1652
76. J Zhou J Chen M Mokotoff 2003 Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer Clin Cancer Res 9 13 4953 4960
77. DN Watkins DM Berman SG Burkholder 2003 Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer Nature 422 6929 313 317
78. H Davies C Hunter R Smith 2005 Somatic mutations of the protein kinase gene family in human lung cancer Cancer Res 65 17 7591 7595
79. A Greystoke J Cummings T Ward 2008 Optimisation of circulating biomarkers of cell death for routine clinical use Ann Oncol 19 5 990 995